Keywords
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

24317 Search results.

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab panels NCT00516321

- 5/31/17 - 1 form, 6 itemgroups, 71 items, 1 language
Itemgroups: Chemistry, Haematology, Liver Chemistry Assessments, Renal Laboratory Parameters, Urinalysis Dipstick, Other Laboratory Screenings
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00516321 https://clinicaltrials.gov/ct2/show/NCT00516321 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab Panels NCT00529568

- 5/31/17 - 1 form, 6 itemgroups, 72 items, 1 language
Itemgroups: Chemistry, Haematology, Liver Chemistry Assessments, Renal Laboratory Parameters, Urinalysis Dipstick, Other Laboratory Screenings
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00529568 https://clinicaltrials.gov/ct2/show/NCT00529568 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Infection Lab panels NCT00996216

- 5/31/17 - 1 form, 6 itemgroups, 49 items, 1 language
Itemgroups: Clinical Chemistry, Haematology, Liver Chemistry, Renal Assessments, Urinalysis Dipstick, Other Laboratory Screenings
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy. NCT00996216 https://clinicaltrials.gov/ct2/show/NCT00996216 Study Type: Interventional Study Design: Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Official Title: An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)

DACAPO-II Study - Interhospitaltransport

- 5/9/17 - 6 forms, 7 itemgroups, 34 items, 1 language
Itemgroups: Interhospitaltransport, Besatzung waehrend des Transports, Qaulifikationen des Transportarztes?, Qualifikationen erster Rettungsassistent, Kommunikation und Dauer, Komplikationen waehrend des Transports, Wenn Transportmitelverzoegerung = ja, was war der Grund fuer die Verzoegerun
Das schwere akute Lungenversagen des Erwachsenen: Einfluss der Versorgungsqualität und individueller Patientenmerkmale auf die gesundheitsbezogene Lebensqualität bei Überlebenden (DACAPO) Surviving ARDS: the influence of quality of care and individual patient characteristics on health-related quality of life (DACAPO)

Externe Klinik

7 itemgroups, 96 items

Studienzentrum

4 itemgroups, 44 items

Verlegung vom Studienzentrum

1 itemgroup, 18 items

Demographische Daten

1 itemgroup, 11 items
1 other form meeting the search is available in the detailed view.

Nursing relevant Questions UKM - Nursing relevant Questions UKM

- 4/6/17 - 1 form, 10 itemgroups, 47 items, 11 languages
Itemgroups: Resting; Sleeping, moving, Getting washed or dressed, Eating and Drinking, Elimination, communication, conscious, meaning of life, Examinations, Miscellaneous
Nursing relevant Questions are a set of questions from the brochure „Pflegerelevante Fragen“, used in University Hospital of Muenster, Germany. The aim of the brochure is to ease the communication between the nursing team and the international patients, who do not speak german. Broschüre "Pflegerelevante Fragen" des Internationalen Patientenmanagements des Universitätsklinikums Münster. Permission granted by Dr. Hofbauer. Source: International Patient Management, University Hospital of Muenster, Germany

CDASH Vital Signs

- 6/20/18 - 1 form, 2 itemgroups, 14 items, 2 languages
Itemgroups: General information, Vital Sign
modified from http://www.cdisc.org

EHR4CR Complete Data Inventory - EHR4CR Data Inventory

- 2/10/17 - 1 form, 13 itemgroups, 122 items, 1 language
Itemgroups: Demographics, Diagnoses and Procedures, Vital Signs, Laboratory, Generic Laboratory Data, Medication, Adverse Events, Medical History, Clinical Findings, ECG, Patient Reported Outcome, Substance Use, Study Participation Status
Compilation of Feasibility, Patient Identification & Recruitment and Clinical Trial Execution data inventories. https://www.ncbi.nlm.nih.gov/pubmed/24410735 https://www.ncbi.nlm.nih.gov/pubmed/25991199 https://www.ncbi.nlm.nih.gov/pubmed/27875988

CDASH Adverse Event - Adverse Event

- 3/9/20 - 1 form, 2 itemgroups, 18 items, 2 languages
Itemgroups: General information, Details Adverse Event
translated and modified from CDASH Adverse Event 2011-10-24 http://www.cdisc.org/

Notifiable Agents according to RKI - Erregerliste RKI

- 9/1/16 - 1 form, 1 itemgroup, 1 item, 2 languages
Itemgroup: Notifiable Agent
Notifiable Agents according to RKI. ODM created by Prof. Dr. Martin Dugas. Semantic annotation created by Prof. Dr. Sylvia Thun and Prof. Dr. Martin Digas

Physician letter (short)

- 7/17/16 - 1 form, 3 itemgroups, 302 items, 1 language
Itemgroups: Current episode, Diagnosis, Current medication
derived from http://www.arztbriefmanager.de/ (Dr. Wolfram Arends, Tutzing, Germany)

Physician letter Internal Medicine

- 7/9/16 - 1 form, 20 itemgroups, 313 items, 1 language
Itemgroups: Medical History, Befund, Clinical presentation, General therapy, Lab, Diagnostics, Cor, Hematology, Gastrointestinal system, Diabetes, Kidney, CNS, Lung, Psychiatrics, Epicrisis, Consultation, Clinical course, Mobilization and social service, Patient education and discharge, Procedere
derived from http://www.arztbriefmanager.de/ (Dr. Wolfram Arends, Tutzing, Germany)

History of Stroke - Ischemic Infarction and Hemorrhage Protocol PhenX Toolkit

- 4/26/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: PhenX - history of stroke protocol
The Stroke Symptoms Form from the Jackson Heart Study is an interviewer-administered questionnaire that captures the history of stroke(s) and associated symptoms such as slurred speech, double vision, loss of vision and paralysis. ODM derived from: https://cde.nlm.nih.gov Primary source: https://www.phenxtoolkit.org/ Recent publication: Hendershot, T., Pan, H., Haines, J., Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M., and Hamilton, C.M. (2015) Using the PhenX toolkit to add standard measures to a study. Curr. Protoc. Hum. Genet. 86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86 Permission to publish granted by Carol M. Hamilton.